Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 17, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, August 16, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrew Fein Maintained (APRE) at Hold with Decreased Target to $80 on, Aug 16th, 2021
Andrew Fein of HC Wainwright & Co., Maintained "Aprea Therapeutics, Inc." (APRE) at Hold with Decreased Target from $120 to $80 on, Aug 16th, 2021.
Andrew has made no other calls on APRE in the last 4 months.
There are 2 other peers that have a rating on APRE. Out of the 2 peers that are also analyzing APRE, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gregory Renza of "RBC Capital" Maintained at Hold with Decreased Target to $100 on, Friday, August 13th, 2021
This is the rating of the analyst that currently disagrees with Andrew
- Jeffrey Hung of "Morgan Stanley" Downgraded from Hold to Sell and Decreased Target to $60 on, Friday, August 13th, 2021
